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Background-—People with reduced glomerular filtration rate (GFR) often have elevated cardiac troponin T (cTnT) levels. It remains
unclear how cTnT levels develop over time in those with chronic kidney disease (CKD). The aim of this study was to prospectively
study the association between cTnT and GFR over time in older advanced-stage CKD patients not on dialysis.
Methods and Results-—The EQUAL (European Quality Study) study is an observational prospective cohort study in stage 4 to 5
CKD patients aged ≥65 years not on dialysis (incident estimated GFR, <20 mL/min/1.73 m²). The EQUAL cohort used for the
purpose of this study includes 171 patients followed in Sweden between April 2012 and December 2018. We used linear mixed
models, adjusted for important groups of confounders, to investigate the effect of both measured GFR and estimated GFR on
high-sensitivity cTnT (hs-cTnT) trajectory over 4 years. Almost all patients had at least 1 hs-cTnT measurement elevated above the
99th percentile of the general reference population (≤14 ng/L). On average, hs-cTnT increased by 16%/year (95% CI, 13–19;
P<0.0001). Each 15 mL/min/1.73 m2 lower mean estimated GFR was associated with a 23% (95% CI, 14–31; P<0.0001) higher
baseline hs-cTnT and 9% (95% CI, 5–13%; P<0.0001) steeper increase in hs-cTnT. The effect of estimated GFR on hs-cTnT
trajectory was somewhat lower than a previous myocardial infarction (15%), but higher than presence of diabetes mellitus (4%) and
male sex (5%).
Conclusions-—In CKD patients, hs-cTnT increases over time as renal function decreases. Lower CKD stage (each 15 mL/min/
1.73 m2 lower) is independently associated with a steeper hs-cTnT increase over time in the same range as other established
cardiovascular risk factors. ( J Am Heart Assoc. 2019;8:e013091. DOI: 10.1161/JAHA.119.013091.)
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C ardiac troponins are proteins in the cardiomyocyte whichare released into the bloodstream and used as a
biomarker for diagnosing an acute coronary event. However,
a substantial proportion of the patients presenting with chest
pain have elevated high-sensitivity cardiac troponin (hs-cTn)
levels without having an acute myocardial infarction (AMI).1
Among those with a permanently elevated hs-cTn above the
reference are patients with advanced chronic kidney disease
(CKD). Given that elevated hs-cTn without signs of AMI is
associated with worse prognosis, measurement of high-
sensitivity cardiac troponin T (hs-cTnT) is acknowledged by
the US Food and Drug Administration to be used for risk
stratification of dialysis patients.2
However, clearance and degradation of cardiac troponins
are not yet fully understood.2 There are 2 possible mecha-
nisms for the increased hs-cTn levels observed in CKD
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patients. First, CKD is associated with cardiovascular mor-
bidity; the raised values could represent continuous myocar-
dial damage caused by long-term exposure to uremic toxins
and/or comorbidities. Thus, an elevated hs-cTn is more
difficult to interpret in patients with CKD, especially in the
setting of a suspected acute coronary event.3 Second, recent
studies have demonstrated that hs-cTnT levels could be
affected by reduced renal clearance per se, especially at
levels just above the 99th percentile concentration of the
reference population.4,5 This has led to the proposal of
estimated (eGFR) glomerular filtration rate (GFR)-corrected hs-
cTn measurements.4,6 Although large studies have evaluated
the cross-sectional association between eGFR and hs-cTn,
there is a lack of prospective, longitudinal studies in stable
CKD patients where the interaction between change in hs-cTn
and eGFR can be studied over time.
The aim of this study was to prospectively study the
association between hs-cTnT and GFR in CKD stage 4 and 5
patients (not on dialysis). Furthermore, we aimed to study the
attributable effect of eGFR on the development of myocardial
strain over time measured by hs-cTn. For this purpose, we
measured GFR, eGFR, and hs-cTnT along with other relevant
clinical data over a 4-year follow-up period in patients aged
>65 years with stage 4 to 5 CKD.
Methods
Study Design and Population
The EQUAL (European Quality Study) study is an ongoing
observational, multicenter, prospective cohort study including
stage 4 to 5 CKD patients not on dialysis receiving routine
medical care in Germany, Italy, the Netherlands, Poland,
Sweden, and the United Kingdom. Patients aged ≥65 years
were included with an incident eGFR<20 mL/min/1.73 m²
calculated by the Modification of Diet in Renal Disease
equation. Patients were excluded if the drop in eGFR resulted
from an acute event or if they had previously received dialysis
or a kidney transplant. Approval was obtained from the
medical ethical committees in each country, and informed
consent was obtained from all patients. A full description of
the study has been published elsewhere.7 The EQUAL cohort
used for the purpose of this study includes 171 patients
recruited at 5 nephrology clinics in Sweden, where hs-cTnT
was collected as an extension to the study protocol. The data
that support the findings of this study are available from the
corresponding author upon reasonable request.
Data Collection
Clinical data were collected between April 2012 to December
2018 through an online case report form on patient demo-
graphics, primary renal disease, laboratory data, and cardio-
vascular risk factors (smoking status, body mass index,
hemoglobin, blood pressure, cholesterol, and diabetes melli-
tus). Data on the following preexisting cardiovascular comor-
bid conditions, confirmed by investigation, were also collected
(definitions provided in Data S1): cerebrovascular disease,
peripheral vascular disease, myocardial infarction, angina
pectoris, congestive heart failure, left ventricular hypertrophy,
hypertension, and cardiac arrhythmias. Study visits were
scheduled at 6-month intervals, and patients were followed
until dialysis initiation, kidney transplantation, death, refusal
for further participation, loss to follow-up, or end of follow-up.
eGFR was calculated from serum creatinine level standardized
to isotope dilution mass spectrometry using the CKD-EPI
(Chronic Kidney Disease Epidemiology Collaboration) equa-
tion.8 GFR was also measured using iohexol clearance at
baseline. In addition, GFR was measured during follow-up
after routine 24-hour urine collection by taking the average of
creatinine clearance and urea clearance, normalized to body
surface area following the Dubois and Dubois formula.
Albumin-creatinine ratio was also determined following rou-
tine 24-hour urine collection. High-sensitivity troponin T was
analyzed at 3 different laboratories using instruments from
Roche Diagnostics (Cobas e601/602, e411, or Modular E;
Roche Diagnostics, Basel, Switzerland). The limit of detection
was 5 ng/L, with an upper limit of 10 000 ng/L, and the
Clinical Perspective
What Is New?
• In our prospective, longitudinal study of chronic kidney
disease patients not on dialysis with an incident estimated
glomerular filtration rate <20 mL/min/1.73 m2, we demon-
strate that lower estimated glomerular filtration rate is
independently associated with a steeper high-sensitivity
cardiac troponin T increase over time, with the effect size in
the same range as other established risk factors, such as
cardiovascular disease, diabetes mellitus, and male sex, and
with effect modification by previous myocardial infarction
and diabetes mellitus.
What Are the Clinical Implications?
• Knowledge of the course and which factors modify the
trajectory of cardiac troponins with progression of chronic
kidney disease will help clinicians in the difficult task to
interpret high-sensitivity cardiac troponin T levels in these
patients.
• In spite of the independent association between lower
estimated glomerular filtration rate and increased high-
sensitivity cardiac troponin T, increasing high-sensitivity
cardiac troponin T over time could reflect the subclinical
development of heart disease resulting from the chronic
kidney disease state.
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coefficient of variation was between 4% and 7%. Primary
kidney disease was classified using the codes of the European
Renal Association–European Dialysis and Transplantation
Association and grouped as glomerulonephritis, diabetes
mellitus, tubulointerstitial disease, hypertension, and miscel-
laneous kidney diseases.
Statistical Analysis
Patient characteristics were reported by hs-cTnT tertiles as
mean values with SDs for normally distributed continuous
variables, as medians with interquartile ranges for skewed
continuous variables, and as proportions for categorical
variables. Differences between hs-cTnT tertiles were tested
using the Kruskal–Wallis test for continuous variables and
the chi-square test for categorical variables. Linear mixed
models were used to model the hs-cTnT trajectory. A
random intercept was included to capture the variation in
hs-cTnT baseline value between patients and a random
slope for time to capture variability in the patient hs-cTn T
trajectory. Because of the nonlinear patient trajectories of
hs-cTnT, the latter was included as a cubic B-spline with 3
equally spaced knots positioned between the minimum and
maximum of follow-up. Using this model, we investigated the
univariable effect of patient characteristics on mean hs-cTnT.
Subsequently, we modeled the mean linear trajectory of hs-
cTnT over time by including time as a fixed effect. In
subsequent models, we investigate the effect of eGFR on hs-
cTnT trajectory (given by the eGFR9time interaction coef-
ficient) and hs-cTnT at baseline (given by the eGFR
coefficient), adjusted for various groups of a priori–defined
confounders. Because of the large amount of missing
measured GFR (mGFR) measurements, we studied the
association between mGFR and hs-cTnT only as a sensitivity
analysis.
We estimated the attributable effect of eGFR on hs-cTn T
by calculating the R2 for various mixed-effects models as
described by Nakagawa and Schielzeth9 and Johnson.10 The
R2 is categorized into 2 types; the marginal R2, which
represents the variance explained by fixed effects, and the
conditional R2, which describes the variance explained by the
entire model. For the purposes of this study, here we report
the former.
Q-Q plots were used to check whether the residuals were
normally distributed, and hs-cTnT was log-transformed to fulfil
this assumption. Consequently, regression coefficients were
exponentiated and interpreted as the mean percent change in
hs-cTn T for each unit increase in determinant. Missing values
are reported in Table S1. All analyses were performed with
SAS (version 9.4; SAS Institute Inc., Cary, NC) and R software




Table 1 describes the baseline characteristics of 171 patients
by hs-cTnT tertile. On average, patients were 75 years old at
inclusion, two-thirds were men, and the measured GFR based
on iohexol clearance (mGFR) at baseline was 19.6 mL/min/
1.73 m2. During the study period, 106 patients reached CKD
stage 5, and 48 patients initiated dialysis (25 on hemodialysis
and 23 on peritoneal dialysis). Median hs-cTnT level at
baseline was 35 ng/L (interquartile range, 24–54). Almost all
patients (170) had at least 1 hs-cTnT measurement elevated
above the 99th percentile of the general reference population
(≤14 ng/L). The 99th percentile reference value, using all
available measurements, was estimated at 132, 264, and 486
for CKD stage 4, CKD stage 5 not on dialysis, and for patients
who initiated dialysis during the study period, respectively.
Patients of male sex, with preexisting diabetes mellitus, heart
failure, and atrial fibrillation, had higher levels of hs-cTnT at
baseline.
Patient Characteristics and Mean hs-cTnT
We included 821 measurements during the predialysis period
in 171 patients, with a median of 3 measurements per patient,
and a median follow-up time of 24.4 months. Individual hs-
cTnT measurements and modelled trajectories are illustrated
in Figure 1, together with the population average hs-cTnT
trajectory. In the unadjusted analysis, reduced renal function
was associated with increased levels of hs-cTnT (Table 2).
Overall, patients with a 5 mL/min/1.73 m2 lower mean eGFR
had 13% higher levels of mean hs-cTnT. Furthermore, patients
with preexisting chronic heart failure had a 34% higher level of
hs-cTnT compared with those without, as did patients with a
history of hypertension (34%), myocardial infarct (33%), angina
pectoris (31%), atrial fibrillation (26%), of male sex (24%),
diabetes mellitus (24%), and patients with lower hemoglobin
(4% per 10 g/L). Interestingly, an inverse relationship was
noted for systolic blood pressure, body mass index, and
cholesterol. An increase by 10 mm Hg mean systolic blood
pressure was associated with a 2% decrease in mean hs-cTnT,
as was body mass index (12% per 10 kg/m2) and cholesterol
(6% per mmol/L). When analyzing these variables with splines
to deal with slight nonlinearity in the relationship with hs-
cTnT, these associations persisted. Mean hs-cTnT was similar
across all 5 nephology clinics (not presented).
The Effect of eGFR on hs-cTnT Trajectory
On average, hs-cTnT increased by 16% (95% CI, 13–19;
P<0.0001) every year. Patients with reduced renal function
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had higher baseline hs-cTnT values and steeper increases in
hs-cTnT (slope) over time (Figure 2). Specifically, each
5 mL/min/1.73 m2 lower mean eGFR was associated with
an 8.2% (95% CI, 4.8–11.5; P<0.0001) higher baseline hs-
cTnT and 3.0% (95% CI, 1.6–4.5; P<0.0001) steeper
increase in hs-cTnT (Table 3). Correspondingly, each
15 mL/min/1.73 m2 lower mean eGFR was associated
with a 23% (95% CI, 14–31; P<0.0001) higher baseline hs-
cTnT and 9% (95% CI, 5–13; P<0.0001) steeper increase in
hs-cTnT. The effect of eGFR on hs-cTnT baseline and hs-
cTnT change over time remained largely unchanged after
adjustment for patient demographics, cardiovascular risk
factors, and preexisting cardiovascular comorbidities
(Table 3). The marginal R2 for eGFR was 14%, meaning
that eGFR explained 14% of the variation in patient hs-cTnT
values.
Table 1. Baseline Patient Characteristics by Troponin T Tertiles






to 379 (N=58) P Value
Demographics
Age, y, mean (SD) 75.4 (6.5) 74.9 (6.4) 75.7 (6.5) 75.6 (6.6) 0.66
Male, % 67 53 74 72 0.03
PRD, % 0.10
Glomerular disease 13 13 10 16
Tubulo-interstitial disease 6 11 7 2
Diabetes mellitus 22 9 31 26
Hypertension 42 45 41 40
Miscellaneous 16 22 10 17
Cardiovascular risk factors
BMI, kg/m2 mean (SD) 27.6 (5.6) 27.8 (6.2) 27.5 (4.3) 27.6 (6.3) 0.91
BP diastolic, mm Hg, mean (SD) 76.5 (11.6) 76 (10.7) 80.3 (11.3) 73 (11.8) 0.01
BP systolic, mm Hg, mean (SD) 145.8 (21.8) 142.3 (21.6) 153.3 (20.5) 141.4 (21.7) 0.01
Total cholesterol, mmol/L, mean (SD) 4.6 (1.2) 4.8 (1.2) 4.6 (1.3) 4.5 (1.3) 0.29
Diabetes mellitus, % 37 20 45 47 0.005
Troponin, ng/L, median (IQR) 35 (24–54) 21 (18–24) 34 (30–40) 65.5 (54–91) NA
Hb, g/L, mean (SD) 118.5 (16.9) 119.7 (15.0) 119.8 (18.0) 116.1 (17.3) 0.28
Current smoking, % 8 5 9 9 0.67
Renal function
eGFR, mL/min/1.73 m2, median (IQR) 17.3 (13.4–21.6) 18.2 (15.7–22.4) 17.3 (12.3–21.6) 16.1 (12.4–20.2) 0.07
mGFR iohexol, mL/min/1.73 m2, median (IQR) 19.5 (14–24) 20 (16–24) 21 (13–24) 18 (12–23) 0.37
mGFR 24-h urine, mL/min/1.73 m2, median (IQR) 15.4 (11.2–19.6) 17.7 (13.9–22.1) 16.8 (12.1–21.1) 12.6 (8.9–16.8) 0.001
ACR, median (IQR) 46.1 (12.5–169.1) 32.0 (5.1–128.3) 60.3 (23.5–163.3) 47.5 (10.3–281.4) 0.15
Preexisting CVD comorbidity
Cerebrovascular, % 16 9 16 22 0.15
Myocardial infarct, % 14 5 19 17 0.08
Angina, % 15 7 17 21 0.12
Peripheral arterial disease, % 13 7 16 17 0.26
Atrial fibrillation, % 16 7 17 24 0.05
Heart failure, % 18 5 14 33 0.001
Left ventricular hypertrophy, % 15 9 19 17 0.30
Hypertension, % 92 87 91 97 0.20
ACR indicates albumin creatinine ratio; BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate (CKDEPI); Hb, hemoglobin; hs-
cTnT, high-sensitivity cardiac troponin T; IQR, interquartile range; mGFR, measured glomerular filtration rate; NA, not applicable; PRD, primary renal disease.
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The effect of a 15 mL/min/1.73 m2 lower eGFR on hs-
cTnT was comparable both at baseline (23%) and over time
(9%) to other factors known to be associated with elevated
troponin levels (Figure S1). Men had 18% (95% CI, 1 to 34;
P=0.07) higher baseline level of hs-cTnT and 5% (95% CI, 0–
10; P=0.05) steeper slopes for hs-cTnT increase compared
with women. Sex explained 11% of the variation in patient hs-
cTnT values. Furthermore, patients with a history of myocar-
dial infarct had 19% (95% CI, 10 to 40; P=0.18) higher
baseline levels of hs-cTnT and 15% (95% CI, 6–22; P<0.0001)
steeper slopes for hs-cTnT increase compared with those
without and explained 10% of the variation in patient hs-cTnT
values. Patients with diabetes mellitus had 19% (95% CI, 1
to 34; P=0.06) higher baseline levels of hs-cTnT and 4% (95%
CI, 1 to 9; P=0.10) steeper slopes for hs-cTnT increase
compared with those without. Diabetes mellitus explained
11% of the variation in patient hs-cTnT values.
Modification of the eGFR Effect on hs-cTnT
Trajectory
We explored potential modifiers of the effect of eGFR on hs-
cTnT baseline and slope. The effect of eGFR on hs-cTnT baseline
(P=0.47) and slope (P=0.75) did not differ by sex, nor was there
evidence of effect modification by the presence of chronic
heart failure (baseline, P=0.85; slope, P=0.11), atrial fibrillation
(baseline, P=0.11; slope, P=0.44) or cerebrovascular disease
(baseline, P=0.18; slope=0.56). Interestingly, the presence of
myocardial infarct strengthened the effect of eGFR on baseline
hs-cTn T (P=0.01), but not on hs-cTnT slope (P=0.22), whereas
the presence of diabetes mellitus (slope, P=0.007; baseline,
P=0.15) or angina pectoris (baseline, P=0.18; slope, P=0.007)
strengthened the effect of eGFR on hs-cTnT slope, but not on
baseline hs-cTnT. We found no evidence of effect modification
from other variables (Figure S2).
Figure 1. Patient hs-cTn T measurements and modeled trajectories, color-coded by eGFR. The population
average trajectory is given in black. eGFR indicates estimated glomerular filtration rate; hs-cTnT, high-
sensitivity cardiac troponin T.
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Effect of Starting Dialysis on hs-cTnT
We performed a sensitivity analysis including patients starting
dialysis. Patients on dialysis had, on average, a 23% (95% CI,
13–34%; P<0.0001) higher hs-cTnT compared with patients
not (yet) on dialysis, even after adjustment for patient
demographics, cardiovascular risk factors, and preexisting
cardiovascular comorbidities. We detected no difference in
effect between patients starting dialysis on hemodialysis
dialysis or peritoneal dialysis (P=0.98), but the sample size
was small and confidence intervals wide.
The Effect of mGFR on hs-cTnT Trajectory
In an additional sensitivity analysis, using the 24-hour urine
collections from 171 patients (526 measurements), we
investigated the effect of mGFR on hs-cTnT trajectory. We
found a similar association as with eGFR; specifically, each
15 mL/min/1.73 m2 lower mean mGFR was associated with
a 16.3% (95% CI, 7.1–24.6; P=0.009) higher baseline hs-cTn T
and a 5.5% (95% CI, 0.7–10.1; P=0.03) steeper increase in hs-
cTnT.
Discussion
In this study of severe-stage CKD patients followed over
4 years in renal outpatient care, we found that hs-cTnT
increased over time and was strongly associated with renal
function both at baseline and during follow-up. The median hs-
cTnT value in this CKD population was around 3 times higher
than the 99th percentile of the reference population, which is
currently used to diagnose AMI, and almost all patients in our
cohort had at least 1 value above that limit during follow-up.
The cross-sectional effect of eGFR per CKD stage (15 mL/
min/1.73 m2) at baseline was independently associated with
hs cTnT and in the same range as other factors (sex, angina,
and diabetes mellitus) previously known to be associated with
higher troponin levels.1 Over time, those with lower eGFRs
had steeper increases in hs-cTnT, and this effect size was
similar to that of patients with previous myocardial infarction.
In addition, the variation of hs-cTnT explained by eGFR was
relatively higher than that of other risk factors.
The interpretation of elevated hs-cTnT values in CKD
patients is challenging in the setting of a suspected AMI.
Patients with renal dysfunction are known to exhibit an
elevated risk of cardiovascular disease and more often
present with atypical symptoms.11 Furthermore, in patients
with chest pain and eGFR <45 mL/min/1.73 m2 but no AMI,
around 65% have elevated hs-cTnT levels.12 The cause of
stable troponin elevation in patients with CKD has been
suggested to be either troponin retention or increased
myocardial stress.2 Reduced renal clearance could be 1
Table 2. The Univariable Association Between Patient
Characteristics and Mean hs-cTnT, Given as the Percent
Change in Mean hs-cTnT for Each Unit Increase in
Determinant
Percent Change in Mean
TnT Per Unit Increase in
Determinant P Value
Demographics
Age (per 5 y) 6% (2% to 14%) 0.16
Male 24% (7–38%) 0.01
PRD
Glomerular disease Reference
Diabetes mellitus 17% (17% to 66%) 0.36
Hypertension 1% (27% to 36%) 0.96
Miscellaneous 11% (38% to 29%) 0.55
Tubulointerstitial
disease
33% (58% to 7%) 0.10
Cardiovascular risk factors
BMI, per 10 kg/m2 12% (20% to 3%) 0.01
BP3 diastolic, per 10 mm
Hg
2% (4% to 0%) 0.07
BP systolic, per 10 mm Hg 2% (3% to 1%) 0.0002
Total cholesterol, per
1 mmol/L
6% (8% to 3%) <0.0001
Diabetes mellitus 24% (6–38%) 0.01
Hb, per 1 g/L 4% (6% to 3%) <0.0001
Current smoking 37% (7% to 103%) 0.11
Renal function
eGFR value (per 5-mL/min/
1.73 m2 increase)
13% (15% to 10%) <0.0001
mGFR 24-h urine mL/min
(per 5-mL/min/1.73 m2
increase)





Cerebrovascular 21% (4% to 40%) 0.09
Myocardial infarct 33% (11–49%) 0.01
Angina 31% (9–48%) 0.01
Peripheral vascular 18% (10% to 39%) 0.18
Atrial fibrillation 26% (4–43%) 0.03
Heart failure 34% (14–49%) 0.002
Left ventricular hypertrophy 12% (15% to 34%) 0.34
Hypertension 34% (5–53%) 0.02
ACR indicates albumin creatinine ratio; BMI, body mass index; BP, blood pressure; CVD,
cardiovascular disease; eGFR, estimated glomerular filtration rate (CKDEPI); Hb,
hemoglobin; hs-cTnT, high-sensitivity cardiac troponin T; mGFR, measured glomerular
filtration rate; PRD, primary renal disease; TnT, troponin T.
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possible mechanism of hs-cTnT retention.13 Although the
intact molecule is too large (37 kDa) to be filtered through the
glomerulus, measured hs-cTnT is degraded to fragments
which could be affected by renal clearance.14 In patients with
CKD, heart failure, and AMI, around 60% to 80% of measured
hs-cTnT had a molecular weight <17 kDa, small enough to
pass through the glomerular membrane.4 However, Friden
et al proposed that extrarenal clearance mechanisms (prob-
ably through scavenger receptors) were likely to be more
important at the high troponin levels commonly observed in
patients with AMI.4 At the low, but stable, hs-cTnT levels
observed in CKD patients, scavenger receptors are less likely
to play an important role given that they do not have such
high affinity for their target proteins. In these patients, a
correlation between measured hs-cTnT and renal clearance
could be expected in a steady-state situation.13 Experimental
data from their study support this hypothesis.4 Clinical data
suggest that acute changes in renal function correlate with
changes in hs-cTnT down to the detection limit.5 In addition,
eGFR-adjusted hs-cTnT discriminates better between AMI and
no AMI in the acute setting, and 1 study also observed
improved predictive performance with eGFR-adjusted tro-
ponin.4,6
In CKD patients, however, troponin levels are higher than
would be expected if only explained by reduced renal
clearance.13 Furthermore, other studies have indicated that
mechanisms other than renal clearance play a larger role.15,16
It has been proposed that cardiac troponin release is the
Figure 2. The unadjusted effect of mean eGFR (mL/min/1.73 m2) on hs-cTn T trajectory.
Table 3. Effect of 5 mL/min/1.73 m2 Lower Mean eGFR on TnT Baseline and Progression Over Time Adjusted for Various Groups
of Confounders (Following the Variables Listed in Table 2)
Model
Baseline Slope
Estimate (95% CI) P Value Estimate (95% CI) P Value
Unadjusted 8.2% (4.8–11.5%) <0.0001 3.0% (1.6–4.5%) <0.0001
Demographics 9.0% (5.6–12.2%) <0.0001 2.5% (1.0–4.0%) 0.001
Cardiovascular risk factors 8.1% (4.6–11.5%) <0.0001 1.8% (0.4–3.3%) 0.01
Cardiovascular comorbidities 8.0% (4.4–11.4%) <0.0001 3.2% (1.7–4.6%) <0.0001
eGFR indicates estimated glomerular filtration rate; TnT, troponin T.
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result of inflammation and chronic myocardial injury associ-
ated with renal dysfunction.17 The interindividual variability of
hs-cTnT is large, also in stable hemodialysis patients, and
elevated levels are associated with worse prognosis, also in
patients without reduced renal function.18 Elevated troponins
are associated with mortality and cardiovascular disease in
CKD patients, both with and without dialysis.19
The independent association between baseline eGFR and
hs-cTnT in our study, together with a relatively high explained
variation of hs-cTnT by eGFR (14%), could mean that renal
clearance per se may influence hs-cTnT levels. However, the
observational methods of our study do not allow us to
separate the attributable effect of renal clearance from that
of, for example, reduced degradation or indirect effects
associated with advanced CKD. In addition, our results show
that hs-cTnT increased over time, and that a reduction in
eGFR by 15 mL/min/1.73 m2 resulted in a 9% steeper
increase in hs-cTnT, remaining statistically significant after
adjusting for other important risk factors. One interpretation
of increasing troponin over time is that it is a sign of
myocardial stress, which, in turn, could be linked to the CKD
state. In our study, the magnitude of this effect is somewhat
lower to that of a previous myocardial infarction (15% steeper
increase), but somewhat higher than the effect of diabetes
mellitus (4% steeper increase). Several risk factors are likely
to contribute to and mediate the increased myocardial stress
and uremic cardiomyopathy. Decreasing renal function causes
neurohormonal activation, which leads to both fluid and
sodium retention with extracellular volume expansion. Several
studies have demonstrated that heart diseases, such as heart
failure and left ventricular hypertrophy, have a high prevalence
in CKD patients.20,21 The CRIC (Chronic Renal Insufficiency
Cohort) study found that echocardiographic findings of
structural heart damage worsened over time with progressive
CKD.22 In the same cohort, a high-sensitivity troponin in the
highest quartile was associated with a higher risk of incident
heart failure.23 Thus, the rise in troponin over time in our
study could reflect a subclinical development of heart disease,
although additional data on cardiac imaging would be required
to confirm this mechanism. Other mechanisms could also
contribute to the development of heart disease and heart
failure in CKD patients. Some of these factors are metabolic
abnormalities, such as alterations in mineral metabolism and
increased levels of phosphate and fibroblast growth factor 23,
anemia, metabolic acidosis, and myocardial stunning, previ-
ously associated with hemodialysis treatment.24
Interestingly, our results indicate that increases in various
cardiovascular risk factors (systolic blood pressure, body
mass index, and cholesterol) were negatively associated with
hs-cTnT. In exploratory analyses (not presented), we found
inverse trends between the presence of preexisting cardio-
vascular comorbidities and these risk factors, suggesting that
the relationship between hs-cTnT and the risk factors are
confounded by the severity of the underlying disease (ie, a low
systolic blood pressure caused by heart failure is associated
with higher troponin levels).
Our study has many strengths. First, the cohort represents
stable CKD patients referred to nephrology. The patients were
incident, included when eGFR dropped below a predefined
level, which minimizes the selection of healthier survivors. The
cohort is well characterized and had rich information on
variables collected both at baseline and during the 4-year
follow-up. Unlike most other cohort studies, hs-cTnT was
measured prospectively throughout follow-up. Although hs-
cTnT was measured at different laboratories, the instruments
used were similar and showed equal limit of detection and
coefficient of variation. There are also some limitations. First,
because of the observational nature of our study, we are
unable to infer causality to our findings. Furthermore, most
patients were whites, and therefore our results may not be
generalizable to other populations. Because of our inclusion
criteria, there were only a limited number of patients in CKD
stage 3, and we cannot rule out that the eGFR/hs-CTnT
association is different when renal function is more preserved.
However, earlier cross-sectional studies indicate that the
association between eGFR and cardiac troponins is present in
the whole spectrum of CKD stages.6 In addition, we lack data
on cardiac imaging, which is required to verify the influence of
myocardial strain on hs-CTnT concentrations. Last, our
sample size may have been too small to rule out type 2
errors in our subanalyses, especially when looking at effect
modification.
In summary, this observational study of a stable nondial-
ysis CKD population shows that there is an independent
association between GFR and hs-cTnT levels. More important,
hs-cTnT increases independently over time in those with lower
eGFR, suggesting that CKD may contribute to chronic
myocardial stress in the same range as established cardio-
vascular disease, although additional data on cardiac imaging
would be required to confirm this mechanism.
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Cerebrovascular disease; patients with a history of cerebrovascular accident with minor or no residual 
symptoms and transient ischemic attacks.  
Peripheral arterial disease; intermittent claudication or bypass for arterial insufficiency, those with 
gangrene or acute arterial insufficiency, and those with untreated thoracic or abdominal aneurysm (6 cm 
or more). 
Myocardial infarction; ST and non-ST elevation myocardial infarction, includes patients with one or more 
definite of probable myocardial infarctions, these patients had ECG and/or enzyme changes. Patients with 
ECG changes alone were not designated as having had a myocardial infarction.  
Angina pectoris; chronic exertional angina, or coronary artery bypass graft, and those admitted with 
unstable angina. 
Congestive heart failure; exertional or paroxysmal nocturnal dyspnea, or responded symptomatically to 
digitalis, diuretics, or afterload reducing agents. It does not include patients on medication but have had 
no symptomatic response, and no evidence of improvement of physical signs. 
Left ventricular hypertrophy; confirmed by echo or ECG. 
Hypertension; sustained blood pressure of >140/90 or using antihypertensives. 
Cardiac arrhythmias; includes arrhythmias, patient with chronic atrial fibrillation or flutter, sick sinus 
syndrome, or ventricular arrhythmias requiring chronic treatment.  
Diabetes; includes patient with retinopathy, neuropathy, or nephropathy, patients who had previous 
hospitalizations for ketoacidosis, hyperosmolar coma, or control, and those with juvenile onset, or brittle 
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eGFR 100 12% 
mGFR iohexol (patients) 85  50% 
mGFR 24-hour urine 283 34% 
ACR 298 36% 
BMI 122 15% 
Cholesterol 138 17% 
Diastolic blood pressure 119 14% 
Systolic blood pressure 119 14% 
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Figure S2A. The modifying effect of sex on the effect eGFR - hs-cTn T. Although men had higher levels of 
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